The agreement assigns recombinant human apoA-I purification to Axplora’s site in France, completing the planned manufacturing network.

The equipment will help formulation scientists assess scale-up risks using small quantities of active pharmaceutical ingredients before commercial manufacturing.

The Valladolid expansion will add capacity for steroid and non-steroid active pharmaceutical ingredients, supporting complex sterile formulations and production.

The expanded BARDA deal adds approximately $270 million in procurement through 2031 as the company advances an investigational antibody against another Ebola virus species.

The bioprocessing supplier opened an X-ray irradiation facility, started a second phase of campus construction, and introduced an automated bulk-product aliquoting platform.

The new Shaoxing site adds 250 cubic meters of reactor capacity, with room for future expansion to more than 400 cubic meters.

The Nanjing site supported a customer program from investigational new drug development through biologics license application submission.

The facility will produce antibody-drug conjugates and other advanced medicines, with capacity for both active pharmaceutical ingredients and finished products.